Premium
Ohr Pharmaceuticals, Inc. (OHRP)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting...
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31...
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Ohr Pharmaceutical, Inc. PR Newswire NEW YORK, Jan. 9, 2019 NEW YORK, Jan. 9, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
LifeX Announces Portfolio Company NeuBase Therapeutics To Merge with Ohr Pharmaceutical LifeX CEO Dr. Dietrich Stephan to take over as NeuBase Therapeutics CEO; LifeX names University of...
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for...
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for...
Dr. Almenoff brings more than 20 years of pharmaceutical executive experience from GlaxoSmithKline and from Furiex Pharmaceuticals, where as President and Chief Medical Officer, she oversaw...
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results...
Dr. Almenoff previously served as President, Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals (now Actavis plc)Ms. Stevens previously served as Chief Corporate...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
